Cargando…
A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options
BACKGROUND: Hereditary amyloidosis refers to a wide spectrum of rare diseases with different causative mutations in the genes of various proteins including transthyretin, apolipoprotein AI and AII, gelsolin, lysozyme, cystatin C, fibrinogen Aα-chain, β2-microglobulin, apolipoprotein CII and CIII. CA...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341640/ https://www.ncbi.nlm.nih.gov/pubmed/30665372 http://dx.doi.org/10.1186/s12881-019-0755-5 |
_version_ | 1783388982367748096 |
---|---|
author | Moutafi, Myrto Ziogas, Dimitrios C. Michopoulos, Spyros Bagratuni, Tina Vasileiou, Vassiliki Verga, Laura Merlini, Giampaolo Palladini, Giovanni Matsouka, Charis Dimopoulos, Meletios A. Kastritis, Efstathios |
author_facet | Moutafi, Myrto Ziogas, Dimitrios C. Michopoulos, Spyros Bagratuni, Tina Vasileiou, Vassiliki Verga, Laura Merlini, Giampaolo Palladini, Giovanni Matsouka, Charis Dimopoulos, Meletios A. Kastritis, Efstathios |
author_sort | Moutafi, Myrto |
collection | PubMed |
description | BACKGROUND: Hereditary amyloidosis refers to a wide spectrum of rare diseases with different causative mutations in the genes of various proteins including transthyretin, apolipoprotein AI and AII, gelsolin, lysozyme, cystatin C, fibrinogen Aα-chain, β2-microglobulin, apolipoprotein CII and CIII. CASE PRESENTATION: Among hereditary amyloidosis subtypes, we describe here a specific case of Apolipoprotein AI amyloidosis (AApoAI), where the diagnosis began from an almost asymptomatic hepatomegaly followed by the development of primary hypogonadism. Baseline laboratory tests showed increased liver enzymes, while imaging tests revealed a suspected infiltrative liver disease. Patient underwent into liver biopsy and histological examination detected the presence of periodic acid-Schiff (−) and Congo-red (+) amorphous eosinophilic material within normal liver tissue. In the typing of amyloid by immunoelectron microscopy, the liver appeared heavily infiltrated by anti-apoAI (+) amyloid fibrils. Gene sequencing and mutational analysis revealed a single-base mutation at position c.251 T > C resulting in an amino acid substitution from leucine to proline in the mature ApoAI protein. This amino acid change led to lower cleavage and ApoAI deposition into the involved organs. Few years later, our patient remaining without treatment, came with symptoms consistent with primary hypogonadism but testicular involvement with ApoAI deposits could not be proven since the patient refused testicular biopsy. Based on this case, we recap the diagnostic challenges, the clinical manifestations, and the potential treatment options for this indolent hereditary amyloidosis subtype. CONCLUSIONS: This case-report enlarges the clinical picture of ApoAI-driven disease and its complex genetic background and in parallel suggests for a more systematic approach in any case with strong suspicion of hereditary amyloidosis. |
format | Online Article Text |
id | pubmed-6341640 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-63416402019-01-24 A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options Moutafi, Myrto Ziogas, Dimitrios C. Michopoulos, Spyros Bagratuni, Tina Vasileiou, Vassiliki Verga, Laura Merlini, Giampaolo Palladini, Giovanni Matsouka, Charis Dimopoulos, Meletios A. Kastritis, Efstathios BMC Med Genet Case Report BACKGROUND: Hereditary amyloidosis refers to a wide spectrum of rare diseases with different causative mutations in the genes of various proteins including transthyretin, apolipoprotein AI and AII, gelsolin, lysozyme, cystatin C, fibrinogen Aα-chain, β2-microglobulin, apolipoprotein CII and CIII. CASE PRESENTATION: Among hereditary amyloidosis subtypes, we describe here a specific case of Apolipoprotein AI amyloidosis (AApoAI), where the diagnosis began from an almost asymptomatic hepatomegaly followed by the development of primary hypogonadism. Baseline laboratory tests showed increased liver enzymes, while imaging tests revealed a suspected infiltrative liver disease. Patient underwent into liver biopsy and histological examination detected the presence of periodic acid-Schiff (−) and Congo-red (+) amorphous eosinophilic material within normal liver tissue. In the typing of amyloid by immunoelectron microscopy, the liver appeared heavily infiltrated by anti-apoAI (+) amyloid fibrils. Gene sequencing and mutational analysis revealed a single-base mutation at position c.251 T > C resulting in an amino acid substitution from leucine to proline in the mature ApoAI protein. This amino acid change led to lower cleavage and ApoAI deposition into the involved organs. Few years later, our patient remaining without treatment, came with symptoms consistent with primary hypogonadism but testicular involvement with ApoAI deposits could not be proven since the patient refused testicular biopsy. Based on this case, we recap the diagnostic challenges, the clinical manifestations, and the potential treatment options for this indolent hereditary amyloidosis subtype. CONCLUSIONS: This case-report enlarges the clinical picture of ApoAI-driven disease and its complex genetic background and in parallel suggests for a more systematic approach in any case with strong suspicion of hereditary amyloidosis. BioMed Central 2019-01-21 /pmc/articles/PMC6341640/ /pubmed/30665372 http://dx.doi.org/10.1186/s12881-019-0755-5 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Case Report Moutafi, Myrto Ziogas, Dimitrios C. Michopoulos, Spyros Bagratuni, Tina Vasileiou, Vassiliki Verga, Laura Merlini, Giampaolo Palladini, Giovanni Matsouka, Charis Dimopoulos, Meletios A. Kastritis, Efstathios A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options |
title | A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options |
title_full | A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options |
title_fullStr | A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options |
title_full_unstemmed | A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options |
title_short | A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options |
title_sort | new genetic variant of hereditary apolipoprotein a-i amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341640/ https://www.ncbi.nlm.nih.gov/pubmed/30665372 http://dx.doi.org/10.1186/s12881-019-0755-5 |
work_keys_str_mv | AT moutafimyrto anewgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions AT ziogasdimitriosc anewgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions AT michopoulosspyros anewgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions AT bagratunitina anewgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions AT vasileiouvassiliki anewgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions AT vergalaura anewgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions AT merlinigiampaolo anewgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions AT palladinigiovanni anewgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions AT matsoukacharis anewgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions AT dimopoulosmeletiosa anewgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions AT kastritisefstathios anewgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions AT moutafimyrto newgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions AT ziogasdimitriosc newgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions AT michopoulosspyros newgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions AT bagratunitina newgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions AT vasileiouvassiliki newgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions AT vergalaura newgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions AT merlinigiampaolo newgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions AT palladinigiovanni newgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions AT matsoukacharis newgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions AT dimopoulosmeletiosa newgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions AT kastritisefstathios newgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions |